Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Share-based Compensation (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Share-based Compensation data on record, last reported at $9.8 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 28.4% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $41.9 million, up 29.34%, while the annual FY2025 figure was $41.9 million, 29.34% up from the prior year.
  • Share-based Compensation reached $9.8 million in Q4 2025 per COLL's latest filing, down from $9.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $11.5 million in Q1 2025 and bottomed at $4.9 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $7.4 million, with a median of $7.0 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: fell 20.9% in 2021, then skyrocketed 54.17% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $4.9 million in 2021, then increased by 15.43% to $5.7 million in 2022, then increased by 23.49% to $7.0 million in 2023, then rose by 8.48% to $7.6 million in 2024, then increased by 28.4% to $9.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $9.8 million in Q4 2025, $9.8 million in Q3 2025, and $10.8 million in Q2 2025.